|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma.
|
9050879 |
1997 |
|
Liver carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcription-PCR analysis showed NY-ESO-1 mRNA expression in a variable proportion of a wide array of human cancers, including melanoma, breast cancer, bladder cancer, prostate cancer, and hepatocellular carcinoma.
|
9050879 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As the proportion of melanomas expressing NY-ESO-1 is 20-40% and only patients with NY-ESO-1(+) tumors have antibody, this would suggest that a high percentage of patients with NY-ESO-1(+) tumors develop an antibody response to NY-ESO-1.
|
9547346 |
1998 |
|
Malignant neoplasm of testis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibodies with specificity for antigens initially recognized by cytotoxic T lymphocytes (CTLs), e.g., MAGE and tyrosinase, have been detected in melanoma patient sera, and CTLs with specificity for NY-ESO-1, a cancer-testis (CT) antigen initially identified by autologous antibody, have recently been identified.
|
9547346 |
1998 |
|
Metastatic melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Comparison of tumor NY-ESO-1 phenotype and NY-ESO-1 antibody response in 62 stage IV melanoma patients showed that all patients with NY-ESO-1(+) antibody had NY-ESO-1(+) tumors, and no patients with NY-ESO-1(-) tumors had NY-ESO-1 antibody.
|
9547346 |
1998 |
|
Stage IV Skin Melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Comparison of tumor NY-ESO-1 phenotype and NY-ESO-1 antibody response in 62 stage IV melanoma patients showed that all patients with NY-ESO-1(+) antibody had NY-ESO-1(+) tumors, and no patients with NY-ESO-1(-) tumors had NY-ESO-1 antibody.
|
9547346 |
1998 |
|
Stage IV Cutaneous Melanoma AJCC v6 and v7
|
0.010 |
Biomarker
|
disease |
BEFREE |
Comparison of tumor NY-ESO-1 phenotype and NY-ESO-1 antibody response in 62 stage IV melanoma patients showed that all patients with NY-ESO-1(+) antibody had NY-ESO-1(+) tumors, and no patients with NY-ESO-1(-) tumors had NY-ESO-1 antibody.
|
9547346 |
1998 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To identify new CT antigens, we constructed an expression cDNA library from a melanoma cell line that expresses a wide range of CT antigens and screened the library with an allogeneic melanoma patient serum known to contain antibodies against two CT antigens, MAGE-1 and NY-ESO-1. cDNA clones isolated from this library identified four CT antigen genes: MAGE-4a, NY-ESO-1, LAGE-1, and CT7.
|
9618514 |
1998 |
|
Malignant neoplasm of testis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify new CT antigens, we constructed an expression cDNA library from a melanoma cell line that expresses a wide range of CT antigens and screened the library with an allogeneic melanoma patient serum known to contain antibodies against two CT antigens, MAGE-1 and NY-ESO-1. cDNA clones isolated from this library identified four CT antigen genes: MAGE-4a, NY-ESO-1, LAGE-1, and CT7.
|
9618514 |
1998 |
|
Squamous cell carcinoma of esophagus
|
0.050 |
Biomarker
|
disease |
BEFREE |
Using a LAGE-I probe to screen a cDNA library from the same melanoma cell line, we identified a closely related gene, which proved to be identical to NY-ESO-I, a gene recently reported to code for an antigen recognized by autologous antibodies in an esophageal squamous cell carcinoma.Gene LAGE-I maps to Xq28.It comprises 3 exons.
|
9626360 |
1998 |
|
Esophageal Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Sequence analysis revealed that CAG-3 encodes an open reading frame identical to NY-ESO-1, which was recently reported to be recognized by autologous serum from a patient with esophageal cancer.
|
9759882 |
1998 |
|
Esophageal carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sequence analysis revealed that CAG-3 encodes an open reading frame identical to NY-ESO-1, which was recently reported to be recognized by autologous serum from a patient with esophageal cancer.
|
9759882 |
1998 |
|
Malignant neoplasm of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Sequence analysis revealed that CAG-3 encodes an open reading frame identical to NY-ESO-1, which was recently reported to be recognized by autologous serum from a patient with esophageal cancer.
|
9759882 |
1998 |
|
Mammary Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Significantly, NY-ESO-1-specific CTL clones were capable of recognizing two HLA-A31-positive fresh and cultured breast tumors.
|
9759882 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genes of the MAGE, BAGE, GAGE, and LAGE-1/NY-ESO-1 families encode antigenic peptides that are presented by HLA class I molecules and that are recognized on human tumors by autologous cytolytic T lymphocytes.
|
10438702 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
NY-ESO-1 gene expression was associated with age older than one year (p = 0.017), more differentiated tumor histology (p = 0.044), elevated urinary vanillylmandelic acid (VMA, p = 0.018) and normal serum ferritin levels (p = 0.023).
|
10472332 |
1999 |
|
Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.
|
10472332 |
1999 |
|
Central neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.
|
10472332 |
1999 |
|
Childhood Neuroblastoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma.
|
10472332 |
1999 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autologous monocyte-derived dendritic cells of cancer patients were incubated with recombinant NY-ESO-1 protein and used in enzyme-linked immunospot (ELISPOT) assays to detect NY-ESO-1-specific CD4(+) T lymphocyte responses.
|
10684854 |
2000 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified three NY-ESO-1-derived peptides presented by DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of two melanoma patients sharing these HLA class II alleles.
|
10684854 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NY-ESO-1 is a member of the cancer-testis family of tumor antigens that elicits strong humoral and cellular immune responses in patients with NY-ESO-1-expressing cancers.
|
10684854 |
2000 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Autologous monocyte-derived dendritic cells of cancer patients were incubated with recombinant NY-ESO-1 protein and used in enzyme-linked immunospot (ELISPOT) assays to detect NY-ESO-1-specific CD4(+) T lymphocyte responses.
|
10684854 |
2000 |
|
Malignant neoplasm of testis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Typing of 33 non-small cell lung cancers for coexpression of a panel of CT antigens revealed a high incidence (60%) of MAGE-3 mRNA expression, followed by MAGE-1 (36%), CT7/MAGE-C1 (30%), CT10 (30%), SSX4 (23%), BRDT (21%), NY-ESO-1 (21%) and HOM-MEL-40/SSX2 (15%).
|
10704737 |
2000 |
|
Malignant neoplasm of lung
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Typing of 33 non-small cell lung cancers for coexpression of a panel of CT antigens revealed a high incidence (60%) of MAGE-3 mRNA expression, followed by MAGE-1 (36%), CT7/MAGE-C1 (30%), CT10 (30%), SSX4 (23%), BRDT (21%), NY-ESO-1 (21%) and HOM-MEL-40/SSX2 (15%).
|
10704737 |
2000 |